Business
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China
Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, diagonostics, and other complementary solutions, today announced that its long-acting botulinum toxin type A product, DAXXIFY (trademark in Chinese Mainland达希斐®), has passed the quality testing from National Institutes for Food and Drug Control of the People's Republic of China ("NIFDC"). This mi
About this update from Sisram Medical Ltd.
[{"type":"text","content":"Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio","length":104,"tagName":"p"},{"type":"text","content":"HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, diagonostics, and other complementary solutions, today announced that its long-acting botulinum toxin type A product, DAXXIFY (trademark in Chinese Mainland达希斐®), has passed the quality testing from National Institutes for Food and Drug Control of the People's Republic of China ("NIFDC"). This milestone confirms that DAXXIFY meets the rigorous requirements set by China's national drug regulatory system regarding quality, safety, and efficacy, successfully completing the final critical step towards market launch.","length":818,"tagName":"p"},{"type":"text","content":"DAXXIFY is the world's first and only long-acting peptide-formulated neuromodulator, containing the active pharmaceutical ingredient botulinum toxin type A (DaxibotulinumtoxinA). It is also the first and only botulinum toxin type A product approved in mainland China featuring proprietary Peptide Exchange Technology (PXT) and a stabilized peptide formulation. Designed to deliver both a long duration of effect and a rapid onset of action, DAXXIFY addresses the temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. Currently, Sisram has reached initial commercial orders with several core medical aesthetic institutions, fully validating market expectations and recognition for this long-acting innovative product and marking its transition from the preparation stage to the sales phase.","length":887,"tagName":"p"},{"type":"text","content":"To advance the commercialization of DAXXIFY, the Company has established a comprehensive professional team responsible for market expansion, clinical support, and supply chain management. The experienced sales and marketing team continues to cultivate core medical networks, deepening strategic collaborations with medical aesthetics institutions. A dedicated medical affairs team empower...